Navigation Links
New approach to leukemia chemotherapy -- is a cure in sight?
Date:3/30/2011

Speaking at the UK National Stem Cell Network conference in York later today (31 March), Professor Tessa Holyoake from the University of Glasgow will discuss a brand new approach to treating chronic myeloid leukaemia (CML) in which a small number of cancer cells persist despite effective therapy thus preventing cure.

CML is a type of blood cancer caused by the infamous "Philadelphia Chromosome" genetic abnormality. It is usually treated using a class of drugs called Tyrosine Kinase Inhibitors and in the majority of cases this treatment is successful, with around 90% of patients recovering from the disease. However in the majority of patients a subset of cancer cells CML stem cells are resistant to Tyrosine Kinase Inhibitors.

"At the moment we are working with 9 patients who still have low level evidence of CML despite Tyrosine Kinase Inhibitor treatment. They are helping us to test the use, in principle, of a new type of drug that specifically deals with the resistant CML stem cells," said Professor Holyoake.

"The drug we are using in the trial is hydroxychloroquine a well established antimalarial drug that has been used commonly since the 1950s and is also used in rheumatoid arthritis. This will allow us to test the principle of using similar drugs to treat CML patients.

"Unfortunately hydroxychloroquine may not be suitable for very long term treatment because of side effects. In particular there is a very low risk of temporary or permanent eye problems. In our trial the patients will take the drug for up to 12 months with very close monitoring of their eye health, which will allow us to intervene at the very earliest sign of an adverse effect," Professor Holyoake continued.

The patients in the trial have already taken a Tyrosine Kinase Inhibitor drug for at least a year, which has reduced the number of cancer cells in their blood to a very low level.

Professor Holyoake's team discovered that CML stem
'/>"/>

Contact: Mike Davies
mike.davies@bbsrc.ac.uk
01-793-414-694
Biotechnology and Biological Sciences Research Council
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Conference highlights UC Berkeleys unique approach to green chemistry
2. Novel approaches to bacterial caries management: An efficacious solution in view?
3. To bring effective therapies to patients quicker, use the team approach
4. University Hospitals system-approach to stroke care increases the use of tPA therapy by 13.5-fold
5. Experimental approach may improve healing of diabetic wounds and bed sores
6. 3rd international conference on innovative approaches in head and neck oncology
7. Study raises safety concerns about experimental cancer approach
8. NIH, Gates Foundation and Colorado State team up to find new approach to a TB vaccine
9. Tufts University calls for moderate approach to teaching personalized genomic testing
10. Cost of Obesity Approaching $300 Billion a Year
11. Mass. General enters collaboration to develop new approach to capturing circulating tumor cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... July 28, 2015 , ... ... that Schneider Electric has completed its upgrade and expansion of its ... with more than 170,000 employees in 134 countries supplying a wide range of ...
(Date:7/28/2015)... , ... July 28, 2015 , ... ... of Directors has authorized the Company, from time to time and depending on ... value of up to $25 million. Repurchases will be made in open market ...
(Date:7/28/2015)... ... July 28, 2015 , ... Women fear developing Alzheimer's disease ... that cancer, heart attack, and stroke are treatable, but there is little an individual ... is to take part in a clinical trial, reports the July 2015 Harvard ...
(Date:7/28/2015)... ... July 28, 2015 , ... A new study published by ... Study Says " sheds light on a possible new treatment option for people living ... of regular HBOT sessions, at least five per week, patients experienced a significant decrease ...
(Date:7/28/2015)... ... ... Most employers have been using multi-tier prescription drug plans for many years, but ... in the use of 4-tier plans, which typically cover the highest cost drugs, as ... to continue, according to UBA. , UBA’s survey finds that, since 2009, the number ...
Breaking Medicine News(10 mins):Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 2Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 3Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 4Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 3Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 2Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 3Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 4Health News:Employers Use of Multi-Tier Pharmacy Benefits Continues to Rise 5
... SUNDAY, Nov. 14 (HealthDay News) -- The Twin Cities of ... number of adult smokers over the last three decades, perhaps ... The decline was due not only to more quitters, but ... to research presented Sunday at the annual meeting of the ...
... researchers in the Department of Neurosciences at the University of ... natural recovery after spinal cord injury in primates. The findings, ... of Nature Neuroscience , may one day lead to ... injuries. While regeneration after severe brain and spinal ...
... adult smokers dramatically decreased during the past three decades ... quitting and fewer picking up the habit, according to ... 2010. The Minnesota Heart Survey, a population-based, serial cross-sectional ... 3,000 and 6,000 participants in each of its six ...
... A brain scan with functional MRI (fMRI) is enough to ... "talk therapy," and so may not need to use psychiatric ... study, being presented at the annual meeting of the Society ... ages 8 to16, who show fear when looking at happy ...
... to treat kidney disease; of that population nearly half ... disease. Dialysis patients are at elevated risk for ... deaths occur because little research has been done to ... high-risk population. Northwestern Medicine cardiologist Rod ...
... 14 (HealthDay News) -- New research suggests that vitamin D ... even though it appears to double the risk for whites. ... that prior research has revealed that blacks are overall more ... a stroke, compared with white patients. Blacks also have a ...
Cached Medicine News:Health News:Minneapolis Study Points to Sharp Drop in Smoking Rates 2Health News:Minneapolis Study Points to Sharp Drop in Smoking Rates 3Health News:Minneapolis Study Points to Sharp Drop in Smoking Rates 4Health News:Research uncovers extensive natural recovery after spinal cord injury 2Health News:Smoking among some adults dropped dramatically in past three decades 2Health News:Smoking among some adults dropped dramatically in past three decades 3Health News:Smoking among some adults dropped dramatically in past three decades 4Health News:Smoking among some adults dropped dramatically in past three decades 5Health News:Smoking among some adults dropped dramatically in past three decades 6Health News:GUMC: fMRI predicts outcome to talk therapy in children with an anxiety disorder 2Health News:Patients receiving dialysis are at a heightened risk for sudden cardiac death 2Health News:Patients receiving dialysis are at a heightened risk for sudden cardiac death 3Health News:Vitamin D Shortage Not Tied to Stroke Deaths in Blacks: Study 2
(Date:7/28/2015)... FORT WORTH, Texas , July 28, 2015 /PRNewswire/ ... Report "Global Dermatology Devices Market by Type (Dermatology Treatment ... MRI, CT), Dermatoscopes, Microscopes]), by Application, by Geography - ... market is expected to reach $11.88 billion by 2019, ... Browse through the TOC of Global Dermatology ...
(Date:7/28/2015)... , July 28, 2015 Research ... addition of the "Global Hearing Aids Market ... The global hearing aids market to grow ... 2014-2019. Factors such as changing ... driving market growth. The market has witnessed immense ...
(Date:7/28/2015)... 2015   CSL Behring announced today ... Authorization Application (MAA) for the company,s investigational long-acting ... recombinant albumin (rIX-FP) for the prophylaxis and treatment ... Upon Swissmedic approval, rIX-FP will provide hemophilia B ... intervals up to 14 days. ...
Breaking Medicine Technology:Global Dermatology Devices Market to be Worth $11.88 Billion by 2019 2Global Dermatology Devices Market to be Worth $11.88 Billion by 2019 3Global Hearing Aids Market 2015-2019 with G N Store Nord, Sonova Holdings & William Demant Dominating 2Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 2Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 3Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B 4
... Phosphagenics,Limited (ASX: POH, AIM: PSG, OTCQX: PPGNY) today ... undertake a Phase 1 transdermal,oxycodone clinical trial aimed ... management product. Phosphagenics has submitted all necessary ... be conducted at CMAX - an independent clinical ...
... Phase 2 clinical development, PRINCETON, N.J., Sept. ... in the discovery and development of novel,small molecule ... 2a,clinical study of PS433540, the company,s lead internal ... receptor antagonist,(DARA) that is being developed as a ...
Cached Medicine Technology:Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 4Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 5
... Intelli-Storeroom™ was developed to create physically secured ... and exits are converted to RFID portals. ... readers and antennas by VerdaSee's Field Engineering ... to assets that are to be tracked. ...
... Mobile Aspects provides hospitals ... products to track all their ... Our RFID systems remove all ... items and people accurately. iRIS, ...
The WatchMate LC model is a cost-effective solution for monitoring a single exit, and provides local notification of an alarm....
... AgileTrac Surgical Services is a Web-based ... to track, manage, and measure patient flow ... process, from admission to discharge. AgileTrac collects ... of care delays your patient might experience. ...
Medicine Products: